A short contemporary history of disseminated intravascular coagulation

Seminars in Thrombosis and Hemostasis

Volumn 2, Issue 1, 2014, Pages

  Levi, Marcel ^a   Poll, Tom Van Der ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

coagulation inhibitors; disseminated intravascular coagulation; fibrinolysis; history; inflammation; microvascular thrombosis; tissue factor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING INHIBITOR; FIBRIN; PLASMIN; PLASMINOGEN; PREKALLIKREIN; PROCOAGULANT; PROTEIN C; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLEEDING; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; PROTHROMBIN TIME; REVIEW; THROMBOCYTE; THROMBOCYTE COUNT; BLOOD; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR COAGULATION; HISTORY; METABOLISM; THROMBOSIS;

BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; THROMBOPLASTIN; THROMBOSIS;

EID: 84909952009     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1395155     Document Type: Review

References (98)

1. Dupuy M. Injections de matière cérébrale dans les veines. Gaz Med Paris: 1834; 2 524
2. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu Paris: 1865; 3 695
3. Naunyn B. I. Untersuchungen über Blutgerinnung im lebenden Thiere und ihre Folgen. Arch Exp Pathol Pharmacol: 1873; 3 1 1 17
4. Wooldridge L. C. Note on the relation of the red cell corpuscules to coagulation. Practitioner: 1886; 38 187
5. Wooldridge L. C. Ueber intravasculare gerinnungen. Arch Ant Physiol Abt (Leipzig): 1886; 397
6. Ratnoff O. D., Pritchard J. A., Colopy J. E. Hemorrhagic states during pregnancy. N Engl J Med: 1955; 253 3 97 102
7. Lasch H. G., Heene D. L., Huth K., Sandritter W. Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy (Verbrauchskoagulopathie). Am J Cardiol: 1967; 20 3 381 391
8. McKay D. G. Disseminated Intravascular Coagulation: An Intermediary Mechanism of Disease. New York, NY Hoeber Medical Division of Harper and Row: 1965
9. Levi M., Ten Cate H. Disseminated intravascular coagulation. N Engl J Med: 1999; 341 8 586 592
10. Levi M., van der Poll T., Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med: 2012; 70 3 114 120
11. Mammen E. F., Anderson G. F., Barnard M. I. Disseminated intravascular coagulation in man. Thromb Diath Haemorrh: 1969; 36 (suppl): 77 80
12. Marder V. J., Feinstein D. I., Colman R. W., Levi M. Consumptive hemorrhagic disorders. In: Marder V. J., Aird W. C., Bennett J. S., Schulman S., White G. C., eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA J. B. Lippincott Company: 2012; 1571 1601
13. Merskey C., Johnson A. J., Kleiner G. J., Wohl H. The defibrination syndrome: clinical features and laboratory diagnosis. Br J Haematol: 1967; 13 4 528 549
14. Müller-Berghaus G., ten Cate H., Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost: 1999; 82 2 706 712
15. Muller-Berghaus G., Blomback M., ten Cate J. W. Attempts to define disseminated intravascular coagulation. In: Muller-Berghaus G., Madlener K., eds. Dic: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation: Proceedings of the Workshop on Disseminated Intravascular (International Congress Series). Amsterdam Excerpta Medica: 1993; 3 8
16. Kalter E. S., Daha M. R., ten Cate J. W., Verhoef J., Bouma B. N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis: 1985; 151 6 1019 1027
17. Nuijens J. H., Huijbregts C. C., Eerenberg-Belmer A. J., et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood: 1988; 72 6 1841 1848
18. Pixley R. A., De La Cadena R., Page J. D., et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest: 1993; 91 1 61 68
19. Sriskandan S., Kemball-Cook G., Moyes D., Canvin J., Tuddenham E., Cohen J. Contact activation in shock caused by invasive group A Streptococcus pyogenes. Crit Care Med: 2000; 28 11 3684 3691
20. Minnema M. C., Pajkrt D., Wuillemin W. A., et al. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood: 1998; 92 9 3294 3301
21. Taylor F. BJ Jr, Chang A., Ruf W., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock: 1991; 33 3 127 134
22. Levi M., ten Cate H., Bauer K. A., et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest: 1994; 93 1 114 120
23. Biemond B. J., Levi M., ten Cate H., et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost: 1995; 73 2 223 230
24. Colman R. W., Schmaier A. H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood: 1997; 90 10 3819 3843
25. Levi M. Keep in contact: the role of the contact system in infection and sepsis. Crit Care Med: 2000; 28 11 3765 3766
26. O'Donnell T. FJ Jr, Clowes G. HJ Jr, Talamo R. C., Colman R. W. Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet: 1976; 143 4 539 545
27. Kaufman N., Page J. D., Pixley R. A., Schein R., Schmaier A. H., Colman R. W. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood: 1991; 77 12 2660 2667
28. Jansen P. M., Pixley R. A., Brouwer M., et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood: 1996; 87 6 2337 2344
29. Levi M., van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost: 2008; 34 5 459 468
30. Esmon C. T. Role of coagulation inhibitors in inflammation. Thromb Haemost: 2001; 86 1 51 56
31. Levi M., de Jonge E., van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med: 2001; 29 (7, Suppl) S90 S94
32. Mesters R. M., Helterbrand J., Utterback B. G., et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med: 2000; 28 7 2209 2216
33. Vary T. C., Kimball S. R. Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol: 1992; 262 2 Pt 1 C445 C452
34. Eckle I., Seitz R., Egbring R., Kolb G., Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler: 1991; 372 11 1007 1013
35. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med: 1986; 163 3 740 745
36. Faust S. N., Levin M., Harrison O. B., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med: 2001; 345 6 408 416
37. Taylor F. BJ Jr, Dahlback B., Chang A. C., et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood: 1995; 86 7 2642 2652
38. Taylor F. BJ Jr, Stearns-Kurosawa D. J., Kurosawa S., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood: 2000; 95 5 1680 1686
39. de Pont A. C., Bakhtiari K., Hutten B. A., et al. Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol: 2006; 134 2 213 219
40. Büller H. R., ten Cate J. W. Antithrombin III infusion in patients undergoing peritoneovenous shunt operation: failure in the prevention of disseminated intravascular coagulation. Thromb Haemost: 1983; 49 2 128 131
41. Mammen E. F. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost: 1998; 24 1 19 25
42. Levi M. Antithrombin in sepsis revisited. Crit Care: 2005; 9 6 624 625
43. Levi M., van der Poll T., Büller H. R. Bidirectional relation between inflammation and coagulation. Circulation: 2004; 109 22 2698 2704
44. Kobayashi M., Shimada K., Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol: 1990; 144 3 383 390
45. de Jonge E., Dekkers P. E., Creasey A. A., et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood: 2000; 95 4 1124 1129
46. Levi M. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med: 2002; 30 8 1914 1915
47. Creasey A. A., Chang A. C., Feigen L., Wün T. C., Taylor F. BJ Jr, Hinshaw L. B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest: 1993; 91 6 2850 2860
48. Brandtzaeg P., Joo G. B., Brusletto B., Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res: 1990; 57 2 271 278
49. Voss R., Matthias F. R., Borkowski G., Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol: 1990; 75 1 99 105
50. Alkjaersig N., Fletcher A. P., Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. II. The significance, mechanism and consequences of defective fibrin polymerization. J Clin Invest: 1962; 41 917 934
51. Levi M., van der Poll T., de Jonge E., ten Cate H. Relative insuffciency of fibrinolysis in disseminated intravascular coagulation. Sepsis: 2000; 3 103 109
52. Biemond B. J., Levi M., Ten Cate H., et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond): 1995; 88 5 587 594
53. Schleef R. R., Bevilacqua M. P., Sawdey M., Gimbrone M. AJ Jr, Loskutoff D. J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem: 1988; 263 12 5797 5803
54. van Hinsbergh V. W., Kooistra T., van den Berg E. A., Princen H. M., Fiers W., Emeis J. J. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood: 1988; 72 5 1467 1473
55. Asakura H., Ontachi Y., Mizutani T., et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med: 2001; 29 6 1164 1168
56. Yamamoto K., Loskutoff D. J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest: 1996; 97 11 2440 2451
57. Nesheim M., Wang W., Boffa M., Nagashima M., Morser J., Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost: 1997; 78 1 386 391
58. Avvisati G., ten Cate J. W., Sturk A., Lamping R., Petti M. G., Mandelli F. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol: 1988; 70 1 43 48
59. Dombret H., Scrobohaci M. L., Ghorra P., et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia: 1993; 7 1 2 9
60. Albarracin N. S., Haust M. D. Intravascular coagulation in promyelocytic leukemia: a case study including ultrastructure. Am J Clin Pathol: 1971; 55 6 677 685
61. Avvisati G., ten Cate J. W., Büller H. R., Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet: 1989; 2 8655 122 124
62. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med: 2010; 38 (2, Suppl) S26 S34
63. Coughlin S. R. Thrombin signalling and protease-activated receptors. Nature: 2000; 407 6801 258 264
64. Camerer E., Cornelissen I., Kataoka H., Duong D. N., Zheng Y. W., Coughlin S. R. Roles of protease-activated receptors in a mouse model of endotoxemia. Blood: 2006; 107 10 3912 3921
65. Slofstra S. H., Bijlsma M. F., Groot A. P., et al. Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation. Blood: 2007; 110 9 3176 3182
66. Esmon C. T. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med: 2002; 196 5 561 564
67. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev: 2001; 184 258 274
68. Taylor F. BJ Jr, Chang A., Esmon C. T., D'Angelo A., Vigano-D'Angelo S., Blick K. E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest: 1987; 79 3 918 925
69. Murakami K., Okajima K., Uchiba M., et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood: 1996; 87 2 642 647
70. Hancock W. W., Tsuchida A., Hau H., Thomson N. M., Salem H. H. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc: 1992; 24 5 2302 2303
71. Hancock W. W., Grey S. T., Hau L., et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation: 1995; 60 12 1525 1532
72. White B., Schmidt M., Murphy C., et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol: 2000; 110 1 130 134
73. Levi M., Dörffler-Melly J., Reitsma P., et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood: 2003; 101 12 4823 4827
74. Lay A. J., Donahue D., Tsai M. J., Castellino F. J. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood: 2007; 109 5 1984 1991
75. Feistritzer C., Sturn D. H., Kaneider N. C., Djanani A., Wiedermann C. J. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J Allergy Clin Immunol: 2003; 112 2 375 381
76. Sturn D. H., Kaneider N. C., Feistritzer C., Djanani A., Fukudome K., Wiedermann C. J. Expression and function of the endothelial protein C receptor in human neutrophils. Blood: 2003; 102 4 1499 1505
77. Hoffmann J. N., Vollmar B., Laschke M. W., et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med: 2004; 32 4 1011 1017
78. Nick J. A., Coldren C. D., Geraci M. W., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood: 2004; 104 13 3878 3885
79. Shimizu S., Gabazza E. C., Taguchi O., et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med: 2003; 167 10 1416 1426
80. Zeng W., Matter W. F., Yan S. B., Um S. L., Vlahos C. J., Liu L. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med: 2004; 32 (5, Suppl): S302 S308
81. Cheng T., Liu D., Griffin J. H., et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med: 2003; 9 3 338 342
82. Riewald M., Petrovan R. J., Donner A., Mueller B. M., Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science: 2002; 296 5574 1880 1882
83. Opal S. M. Interactions between coagulation and inflammation. Scand J Infect Dis: 2003; 35 9 545 554
84. Harada N., Okajima K., Kushimoto S., Isobe H., Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood: 1999; 93 1 157 164
85. Mizutani A., Okajima K., Uchiba M., et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood: 2003; 101 8 3029 3036
86. Uchiba M., Okajima K., Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res: 1998; 89 5 233 241
87. Kaneider N. C., Förster E., Mosheimer B., Sturn D. H., Wiedermann C. J. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb Haemost: 2003; 90 6 1150 1157
88. Taylor F. BJ Jr, Toh C. H., Hoots W. K., Wada H., Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost: 2001; 86 5 1327 1330
89. Wada H., Hatada T., Okamoto K., et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am J Hematol: 2010; 85 9 691 694
90. Horan J. T., Francis C. W. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost: 2001; 27 6 657 666
91. Bakhtiari K., Meijers J. C., de Jonge E., Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med: 2004; 32 12 2416 2421
92. Toh C. H., Hoots W. K. SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost: 2007; 5 3 604 606
93. Levi M. Disseminated intravascular coagulation in cancer patients. Best Pract Res Clin Haematol: 2009; 22 1 129 136
94. Thachil J., Toh C. H. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev: 2009; 23 4 167 176
95. Dhainaut J. F., Yan S. B., Joyce D. E., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost: 2004; 2 11 1924 1933
96. Wada H., Gabazza E. C., Asakura H., et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol: 2003; 74 1 17 22
97. Levi M., van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med: 2013; 8 1 23 32
98. Levi M., Schultz M., van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost: 2013; 39 5 559 566